Summary | US-listed drug maker Simcere Pharmaceutical (NYSE:
SCR) must be eagerly looking forward to completing its pending
privatization, following the release of its latest quarterly
results that show the fast-growing Chinese healthcare market is
suddenly losing some of its luster. Simcere is just the latest
drug maker to encounter headwinds in China, where fierce ...
youngchinabiz.com | 08 March 2016